PREdicting Atrial Fibrillation or Flutter (PREDATE-AF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Keesler Air Force Base Medical Center
Sponsor:
Information provided by (Responsible Party):
Keesler Air Force Base Medical Center
ClinicalTrials.gov Identifier:
NCT01851902
First received: May 2, 2013
Last updated: May 8, 2013
Last verified: May 2013

May 2, 2013
May 8, 2013
May 2013
May 2015   (final data collection date for primary outcome measure)
Incidence of Atrial Fibrillation [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Incidence rate of AF calculated in each arm as the number of participants with an initial episode of AF lasting greater than or equal to six minutes divided by the total number of participants in that arm.
Same as current
Complete list of historical versions of study NCT01851902 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
PREdicting Atrial Fibrillation or Flutter
PREdicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF)"

The purpose of this study is to determine, through continuous monitoring with a cardiac monitoring device placed under the skin, the incidence of atrial fibrillation or flutter (AF). The cardiac monitor will be placed in patients without symptoms but at risk for AF. It is hoped that this information may assist health care professionals in treatment decisions related to the early identification of patients at high risk for AF.

Background: Atrial fibrillation and atrial flutter (AF) are common cardiac arrhythmias that confer a substantial stroke burden largely because the vast majority of AF is asymptomatic and identified after a stroke has occurred. Until recently, only intermittent cardiac monitors were available, with most AF episodes remaining undetected due to poor sensitivity. Health care providers estimate the risk of stroke in AF patients using a patient's comorbidity profile to determine who should be treated with oral anticoagulant therapy for stroke prevention. The incidence of AF in patients with high stroke risk comorbidities is not known. The Medtronic Reveal insertable cardiac monitor (ICM) is a continuous monitoring device with excellent AF detection.

Purpose and Study Objectives: The purpose of the PREDATE AF study is to determine the incidence of AF in asymptomatic patients at high risk for having AF in order to determine which patient characteristics are most predictive of the development of AF. The primary objective is to determine the AF incidence rate; secondary objectives include identifying the most important predictors of AF onset and identifying how physicians respond once AF has been discovered.

Study Design: The trial is a prospective, single arm, open-label, single center clinical study which will enroll up to 360 patients at high risk of having AF based upon their comorbidity profile, who will then receive an ICM. Enrolled subjects will be followed for a minimum of 18 months to monitor for the detection of AF. Monthly ICM data transmissions will be the mechanism of AF detection, and this information will be utilized to determine the AF incidence rate

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

The PREDATE AF trial is a prospective, single arm, open-label, single center clinical study to evaluate the incidence of AF in patients that are suspected to be at high risk of having AF, as defined by a modified CHA2DS2-VASc score.

  • Atrial Fibrillation
  • Atrial Flutter
Not Provided
  • CHA2DS2-VASc Score 2 - 4
    Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
  • CHA2DS2-VASc Score 5 - 7
    Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
  • CHA2DS2-VASc Score 8 - 10
    Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
360
May 2015
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient meets the approved FDA indication to receive the ICM
  • Patient is suspected, based on demographics, to be at high risk of having AF, as determined by the clinical investigator
  • Patient has a CHA2DS2-VASc score ≥ 2 [Note: stroke/TIA criterion as part of the CHA2DS2-VASc score for this trial is limited to either an ischemic stroke or TIA, which occurred more than one year prior to enrollment.]
  • Patient is 18 years of age or older
  • Patient has a life expectancy of 18 months or more

Exclusion Criteria:

  • Patient has a documented history of AF or atrial flutter
  • Patient has a symptom complex consistent with an arrhythmia (where an ICM may have an alternate indication for use)
  • Patient had an ischemic stroke or TIA within past year prior to enrollment
  • Patient has a history of a hemorrhagic stroke
  • Patient is currently implanted with a permanent pacemaker, insertable loop recorder, implantable defibrillator, cardiac resynchronization therapy device (pacemaker or defibrillator)
  • NYHA Class IV Heart Failure patient
  • Patient had heart surgery within previous 90 days prior to enrollment
  • Patient had an MI within the previous 90 days prior to enrollment
  • Patient is taking chronic immunosuppressant therapy
  • Patient is taking an anti-arrhythmic drug
  • Patient is contraindicated for long term anticoagulation medication
  • Patient is taking a long-term anticoagulation medication
  • Any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional / psychological diagnosis)
  • Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from the principal investigator
  • Patient has a creatinine clearance <30 ml/min or is on dialysis
  • Active pregnancy
Both
18 Years and older
No
Contact: Steven Kindsvater, MD 228-376-3500 steven.kindsvater@us.af.mil
Contact: Jay Nasir, MD 228-376-3500 jay.nasir@us.af.mil
United States
 
NCT01851902
FKE20130012H
No
Keesler Air Force Base Medical Center
Keesler Air Force Base Medical Center
Not Provided
Not Provided
Keesler Air Force Base Medical Center
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP